A certification process for validated real-world data sources and public disclosure of FDA assessments of real-world evidence in drug applications are urged by stakeholders in the most recent set of comments responding to the agency’s guidance on electronic medical records and health claims.
The comments suggest a common desire to leverage prior validation work and regulatory experience, rather than having to recreate the proverbial wheel each time a dataset is used in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?